WAM
VRTX icon

Worth Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Worth Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$952K Buy
+1,820
New +$932K 0.28% 97
2024
Q4 		– Sell
-828
Closed -$385K – 169
2024
Q3 		$385K Buy
+828
New +$398K 0.21% 85

Other funds holding VRTX

MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
GGS
Galvin Gaustad & Stein Scottsdale, Arizona $1.33B AUM 13.15% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
LJHT
Laurie J. Hall Trustee $314M AUM 27.43% 1-Year Est. Return
CFG
Cooper Financial Group Irvine, California $1.26B AUM 21.18% 1-Year Est. Return

Worth Asset Management's VRTX Position: Q3 2026 in Review

Worth Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 1,820 shares worth $952K. The stake represents 0.28% of the portfolio and ranks #97 among its holdings. This is a return to the name: Worth Asset Management previously reported a position in VRTX as recently as Q3 2024.

Worth Asset Management first reported a position in VRTX in Q3 2024 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Worth Asset Management held 1,820 shares of Vertex Pharmaceuticals worth $952K as of Q3 2026.
  • Vertex Pharmaceuticals was a new Worth Asset Management position in Q3 2026.
  • Vertex Pharmaceuticals made up 0.28% of Worth Asset Management's portfolio in Q3 2026, its #97 holding.
  • Worth Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 2 quarters since.
  • 66 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Worth Asset Management's 13F filing for Q3 2026, filed 7 Oct 2026.